Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 7,47 € ( 112,22 %). Der Median liegt bei 7,47 € ( 112,22 %).
Kaufen |
1 |
Halten |
0
|
Verkaufen |
0 |
Scoring-Modelle
Dividenden-Strategie | 0 / 15 |
HGI-Strategie | 5 / 18 |
Levermann-Strategie | 2 / 13 |
Beliebteste Broker
News
- 23.04. - 20:30 Uhr
Neuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference Call
MALVERN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release first quarter 2024 financial and operating results prior to market open on Tuesday, May 7th, 2024. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/i3t5h9gs . To listen to the conference call on your telephone, participants may register for the call here . While it is not required, it is recommended you join 10 minutes prior to the event start. About Neuronetics Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn't helped. In the United States, NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression). NeuroStar is also indicated as a first-line, adjunct for MDD in adolescents 15 and older. NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults with over 6.1 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS system for depression, including the world's largest depression Outcomes Registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, www.neurostar.com. Investor Contact: Mike Vallie or Mark KlausnerICR Westwicke443-213-0499ir@neuronetics.com Media Contact: EvolveMKD646-517-4220NeuroStar@evolvemkd.com » Mehr auf globenewswire.com
- 01.04. - 15:56 Uhr
Neuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression
Neuronetics (STIM) announces the FDA's approval of NeuroStar Advanced Therapy, which is likely to aid in the treatment of depression in adolescents by acting as a supplement. » Mehr auf zacks.com
- 08.03. - 14:11 Uhr
Neuronetics (STIM) Progresses in MRD and TRD With New Deal
The collaboration between Neuronetics (STIM) and TCN holds particular significance in the realm of treatment-resistant depression. » Mehr auf zacks.com
Unternehmenszahlen
(EUR) | Dez. 2023 | |
---|---|---|
Umsatz | 18,38 Mio | 8,32% |
Bruttoeinkommen | 13,81 Mio | 7,29% |
Nettoeinkommen | 4,86 Mio | 41,05% |
EBITDA | 3,55 Mio | 46,20% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 104,16 Mio € |
Anzahl Aktien | 29,76 Mio |
52 Wochen-Hoch/Tief | 4,73 € - 0,96 € |
Dividenden | Nein |
Beta | 2,44 |
KGV (PE Ratio) | 3,54 |
KGWV (PEG Ratio) | 0,78 |
KBV (PB Ratio) | 3,19 |
KUV (PS Ratio) | 1,56 |
Unternehmensprofil
Neuronetics, Inc. ist ein Medizintechnikunternehmen im kommerziellen Stadium, das Produkte für Patienten mit neurologischen Störungen in den Vereinigten Staaten und international entwickelt und vermarktet. Das Unternehmen bietet das NeuroStar Advanced Therapy System an, eine nicht-invasive und nicht-systemische Behandlung in der Praxis zur Behandlung erwachsener Patienten mit schweren depressiven Störungen. Das NeuroStar Advanced Therapy System nutzt die transkranielle Magnetstimulation, um ein gepulstes Magnetfeld von MRT-Stärke zu erzeugen, das elektrische Ströme induziert, die bestimmte Hirnregionen stimulieren, die mit der Stimmung in Verbindung stehen. Das Unternehmen vertreibt seine Produkte über sein Vertriebs- und Kundendienstteam an Psychiater. Neuronetics, Inc. wurde im Jahr 2001 gegründet und hat seinen Hauptsitz in Malvern, Pennsylvania.
Name | NEURONETICS INC. DL-,01 |
CEO | Keith J. Sullivan |
Sitz | Malvern,
pa USA |
Website | |
Industrie | Gebrauchsgüter |
Börsengang | 28.06.2018 |
Mitarbeiter | 203 |
Ticker Symbole
Börse | Symbol |
---|---|
NASDAQ | STIM |
Frankfurt | NRC.F |
München | NRC.MU |
Düsseldorf | NRC.DU |
Assets entdecken
Shareholder von NEURONETICS INC. DL-,01 investieren auch in folgende Assets